- Home
- BTMD
BTMD
Biote Corp.
as 08-29-2025 9:37am EST
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | IRVING |
| Market Cap: | 127.8M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 223.9K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.88 | EPS Growth: | 642.53 |
| 52 Week Low/High: | $2.76 - $6.98 | Next Earning Date: | 08-06-2025 |
| Revenue: | $199,073,000 | Revenue Growth: | 6.32% |
| Revenue Growth (this year): | -0.34% | Revenue Growth (next year): | 4.85% |
Latest Biote Corp. News
BTMD Breaking Stock News: Dive into BTMD Ticker-Specific Updates for Smart Investing
Business Wire
3 months ago
Biote Names Rich Barrera to Board of Directors
Simply Wall St.
4 months ago
biote First Quarter 2025 Earnings: Beats Expectations
Simply Wall St.
4 months ago
biote Corp. Just Recorded A 469% EPS Beat: Here's What Analysts Are Forecasting Next
GuruFocus.com
4 months ago
Biote Corp (BTMD) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic Restructuring ...
Zacks
4 months ago
Biote Corp. (BTMD) Q1 Earnings and Revenues Surpass Estimates
Business Wire
4 months ago
Biote Reports First Quarter 2025 Financial Results
Business Wire
4 months ago
Biote Schedules First Quarter 2025 Financial Results Release and Conference Call
Insider Monkey
5 months ago
biote Corp. (BTMD): Insider Were Buying In Q1 2025
Compare BTMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BTMD Biote Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.